Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19
Status:
COMPLETED
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
Collagen-polyvinylpyrrolidone (collagen-PVP) and pirfenidone have the ability to control cytokine storms. This work explores the therapeutic effects of both, on the early treatment of patients with severe COVID-19. The hospital stay, quick COVID-19 severity index (qCSI) and admission to the ICU were statistically significantly lower when the patients were treated with collagen-PVP or pirfenidone, compared to the controls treated with dexamethasone alone.